Jupiter Neurosciences Showcases Nugevia鈩� PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia鈩� PWR, a mitochondrial health supplement designed to enhance cellular energy, endurance, and recovery. The product leverages the company's proprietary JOTROL鈩� resveratrol-based platform technology and will be commercially available in Fall 2025.
The supplement combines JOTROL鈩�, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials, with NovaSOL庐 solubilized CoQ10. The product targets the longevity and wellness markets, projected to reach $8 trillion by 2030. PWR is designed as a two-capsule daily regimen and will join GLO in Jupiter's Nugevia鈩� product line.
The company positions PWR as a strategic revenue opportunity, aiming to generate high-margin returns to support its therapeutic development programs while addressing growing consumer demand for scientifically validated supplements.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato il lancio di Nugevia鈩� PWR, un integratore per la salute mitocondriale progettato per migliorare l'energia cellulare, la resistenza e il recupero. Il prodotto sfrutta la tecnologia proprietaria JOTROL鈩�, basata sul resveratrolo, e sar脿 disponibile commercialmente nell'autunno 2025.
L'integratore combina JOTROL鈩�, che ha mostrato un aumento di nove volte della biodisponibilit脿 del resveratrolo nelle prove di Fase I, con NovaSOL庐 CoQ10 solubilizzato. Il prodotto si rivolge ai mercati della longevit脿 e del benessere, previsti raggiungere un valore di 8 trilioni di dollari entro il 2030. PWR 猫 pensato come un regime quotidiano di due capsule e si unir脿 a GLO nella linea di prodotti Nugevia鈩� di Jupiter.
L'azienda considera PWR un'opportunit脿 strategica di ricavo, con l'obiettivo di generare ritorni ad alto margine per sostenere i suoi programmi di sviluppo terapeutico, rispondendo al contempo alla crescente domanda dei consumatori di integratori convalidati scientificamente.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado el lanzamiento de Nugevia鈩� PWR, un suplemento para la salud mitocondrial dise帽ado para mejorar la energ铆a celular, la resistencia y la recuperaci贸n. El producto utiliza la tecnolog铆a patentada JOTROL鈩�, basada en resveratrol, y estar谩 disponible comercialmente en el oto帽o de 2025.
El suplemento combina JOTROL鈩�, que mostr贸 un aumento de nueve veces en la biodisponibilidad del resveratrol en los ensayos de Fase I, con CoQ10 solubilizado NovaSOL庐. El producto est谩 dirigido a los mercados de longevidad y bienestar, que se proyectan alcanzar un valor de 8 billones de d贸lares para 2030. PWR est谩 dise帽ado como un r茅gimen diario de dos c谩psulas y se unir谩 a GLO en la l铆nea de productos Nugevia鈩� de Jupiter.
La compa帽铆a posiciona PWR como una oportunidad estrat茅gica de ingresos, con el objetivo de generar retornos de alto margen para apoyar sus programas de desarrollo terap茅utico, mientras responde a la creciente demanda de los consumidores por suplementos validados cient铆ficamente.
Jupiter Neurosciences (NASDAQ: JUNS)電� 靹疙彫 鞐愲剤歆�, 歆�甑牓 氚� 須岆车霠レ潉 頄レ儊鞁滍偆旮� 鞙勴暣 靹り硠霅� 氙疙啝旖橂摐毽晞 瓯搓皶 氤挫“鞝滌澑 Nugevia鈩� PWR鞚� 於滌嫓毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞝滍拡鞚� 須岇偓鞚� 霃呾爯鞝侅澑 JOTROL鈩� 霠堨姢氩犽澕韸鸽· 旮半皹 頂岆灚韽� 旮办垹鞚� 頇滌毄頃橂┌, 2025雲� 臧�鞚�鞐� 靸侅梾鞝侅溂搿� 於滌嫓霅� 鞓堨爼鞛呺媹雼�.
鞚� 氤挫“鞝滊姅 1靸� 鞁滍棙鞐愳劀 霠堨姢氩犽澕韸鸽· 靸濎泊鞚挫毄毳犾澊 9氚� 歃濌皜頃� JOTROL鈩㈥臣 NovaSOL庐 鞖╉暣順� CoQ10鞚� 瓴绊暕頄堨姷雼堧嫟. 鞚� 鞝滍拡鞚� 2030雲勱箤歆� 8臁� 雼煬鞐� 雼暊 瓴冹溂搿� 鞓堨儊霅橂姅 鞛レ垬 氚� 鞗半媹鞀� 鞁滌灔鞚� 氇╉憸搿� 頃╇媹雼�. PWR鞚� 頃橂（ 霊� 旌§姁 氤奠毄 觳搓硠搿� 靹り硠霅橃棃鞙茧┌, Jupiter鞚� Nugevia鈩� 鞝滍拡甑办棎 GLO鞕� 頃粯 頃╇頃� 鞓堨爼鞛呺媹雼�.
須岇偓電� PWR鞚� 鞝勲灥鞝� 靾橃澋 旮绊殞搿� 鞛愲Μ毵り箑頃橃棳, 旃橂 臧滊皽 頂勲攴鸽灗鞚� 歆�鞗愴晿電� 瓿犾垬鞚奠潉 彀届稖頃橁碃 瓿柬暀鞝侅溂搿� 瓴�歃濍悳 氤挫“鞝滌棎 雽�頃� 靻岆箘鞛� 靾橃殧 歃濌皜鞐� 雽�鞚戫晿電� 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Jupiter Neurosciences (NASDAQ : JUNS) a annonc茅 le lancement de Nugevia鈩� PWR, un compl茅ment pour la sant茅 mitochondriale con莽u pour am茅liorer l'茅nergie cellulaire, l'endurance et la r茅cup茅ration. Ce produit utilise la technologie propri茅taire JOTROL鈩� 脿 base de resv茅ratrol et sera disponible commercialement 脿 l'automne 2025.
Le compl茅ment associe JOTROL鈩�, qui a d茅montr茅 une augmentation de neuf fois la biodisponibilit茅 du resv茅ratrol lors des essais de phase I, 脿 la CoQ10 solubilis茅e NovaSOL庐. Ce produit cible les march茅s de la long茅vit茅 et du bien-锚tre, estim茅s 脿 8 000 milliards de dollars d'ici 2030. PWR est con莽u pour 锚tre pris en deux capsules par jour et viendra compl茅ter la gamme Nugevia鈩� de Jupiter, aux c么t茅s de GLO.
L'entreprise positionne PWR comme une opportunit茅 strat茅gique de revenus, visant 脿 g茅n茅rer des marges 茅lev茅es pour soutenir ses programmes de d茅veloppement th茅rapeutique tout en r茅pondant 脿 la demande croissante des consommateurs pour des compl茅ments scientifiquement valid茅s.
Jupiter Neurosciences (NASDAQ: JUNS) hat die Einf眉hrung von Nugevia鈩� PWR angek眉ndigt, einem Nahrungserg盲nzungsmittel zur mitochondrialen Gesundheit, das darauf ausgelegt ist, die zellul盲re Energie, Ausdauer und Erholung zu verbessern. Das Produkt nutzt die firmeneigene JOTROL鈩�-Technologie auf Resveratrol-Basis und wird im Herbst 2025 kommerziell erh盲ltlich sein.
Das Supplement kombiniert JOTROL鈩�, das in Phase-I-Studien eine neunfach erh枚hte Resveratrol-Bioverf眉gbarkeit zeigte, mit NovaSOL庐 l枚slichem CoQ10. Das Produkt richtet sich an die M盲rkte f眉r Langlebigkeit und Wellness, die bis 2030 voraussichtlich 8 Billionen US-Dollar erreichen werden. PWR ist als t盲gliche Einnahme von zwei Kapseln konzipiert und wird sich der GLO-Produktlinie in Jupiters Nugevia鈩�-Portfolio anschlie脽en.
Das Unternehmen sieht in PWR eine strategische Umsatzchance, mit dem Ziel, margenstarke Ertr盲ge zu generieren, um seine therapeutischen Entwicklungsprogramme zu unterst眉tzen und gleichzeitig der wachsenden Verbrauchernachfrage nach wissenschaftlich validierten Nahrungserg盲nzungsmitteln gerecht zu werden.
- JOTROL demonstrated 9x increase in resveratrol bioavailability in Phase I trials
- Product targets longevity and wellness markets projected to reach $8 trillion by 2030
- Strategic expansion into high-margin consumer supplement market
- Leverages existing proprietary technology across both pharmaceutical and consumer verticals
- None.
PWR delivers science-driven cellular energy and recovery support as part of Jupiter鈥檚 expanding longevity supplement portfolio
Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL鈩�, a patented resveratrol-based platform, is pleased to unveil Nugevia鈩� PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, projected to reach
Clinically Validated Cellular Fuel
Built on the same pharmaceutical-grade delivery platform behind Jupiter's CNS drug candidates, PWR pairs JOTROL鈩� with a curated blend of mitochondrial support ingredients to help optimize energy production, protect against oxidative stress, and enhance physical performance. The formulation was developed for adults seeking sustained strength, metabolic resilience, and recovery support grounded in clinical science.
"With PWR, we are tapping into the bioenergetic core of healthy aging," said Christer Ros茅n, Chairman and CEO of Jupiter Neurosciences. "By leveraging our JOTROL鈩� platform beyond the clinic, we're offering a science-first approach to vitality and endurance that meets growing demand from consumers who want more than just a quick energy boost."
Advanced Mitochondrial Science for Endurance and Recovery
JOTROL鈩�, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, promotes mitochondrial biogenesis and energy metabolism through activation of longevity pathways. In PWR, JOTROL鈩� is combined with NovaSOL庐 solubilized CoQ10, a highly bioavailable antioxidant proven to enhance mitochondrial energy production and muscle function. Together, these ingredients create a powerful synergy鈥攂oosting both the quantity and quality of mitochondria, resulting in improved energy, endurance, and muscle recovery.
Taken together, these ingredients work in synergy to:
- Boost mitochondrial energy output
- Reduce exercise-related oxidative stress
- Support muscle recovery and stamina
- Promote sustained physical and mental performance
A Strategic Growth Catalyst
PWR reinforces Jupiter's strategy of monetizing its proprietary science across both pharmaceutical and consumer verticals. The supplement joins GLO in the broader Nugevia鈩� rollout, which the Company expects to serve as a high-margin revenue driver supporting therapeutic development.
"Each product in the Nugevia line represents both a scientific achievement and a strategic revenue opportunity," added Ros茅n. "With PWR, we're providing a differentiated option in the crowded energy space鈥攐ne that delivers long-term benefits, not just a short-term boost."
Nugevia PWR is designed as a two-capsule-per-day regimen for optimal compliance and absorption.
A digital press kit, including high-resolution product imagery and key brand information, is available at .
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia鈩� product line. Both efforts are powered by JOTROL鈩�, Jupiter鈥檚 proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company鈥檚 prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson鈥檚 disease, includeing indications such as Alzheimer鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
About JOTROL
Resveratrol is one of the world鈥檚 most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL鈩� achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer鈥檚 Disease trial, and Yui et al., Friedreich鈥檚 Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL鈩� trials, were published in the Journal of Alzheimer鈥檚 Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL鈩� toward a Phase IIa trial in Parkinson鈥檚 Disease.
In addition to its therapeutic applications, JOTROL鈩� serves as the foundation for Jupiter鈥檚 Nugevia鈩� consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia鈩� introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
FAQ
When will Jupiter Neurosciences (JUNS) launch Nugevia PWR?
What is the key technology behind Jupiter Neurosciences' Nugevia PWR supplement?
What is the recommended dosage for Jupiter Neurosciences' Nugevia PWR?
What market opportunity is Jupiter Neurosciences (JUNS) targeting with Nugevia PWR?
How does Nugevia PWR fit into Jupiter Neurosciences' business strategy?
